Clear Harbor Asset Management LLC Invests $1.44 Million in Perrigo Company plc (NYSE:PRGO)

Clear Harbor Asset Management LLC purchased a new stake in Perrigo Company plc (NYSE:PRGO - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 55,015 shares of the company's stock, valued at approximately $1,443,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Diamond Hill Capital Management Inc. increased its holdings in shares of Perrigo by 83.2% during the 2nd quarter. Diamond Hill Capital Management Inc. now owns 1,940,067 shares of the company's stock worth $49,821,000 after buying an additional 881,191 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Perrigo by 675.5% during the 2nd quarter. AQR Capital Management LLC now owns 970,637 shares of the company's stock valued at $24,926,000 after acquiring an additional 845,470 shares during the period. National Bank of Canada FI acquired a new position in Perrigo in the 1st quarter valued at about $19,040,000. Copeland Capital Management LLC lifted its position in shares of Perrigo by 23.1% during the third quarter. Copeland Capital Management LLC now owns 2,482,544 shares of the company's stock worth $65,117,000 after purchasing an additional 465,161 shares in the last quarter. Finally, Deprince Race & Zollo Inc. grew its holdings in shares of Perrigo by 11.2% in the second quarter. Deprince Race & Zollo Inc. now owns 3,882,438 shares of the company's stock valued at $99,701,000 after purchasing an additional 391,646 shares in the last quarter. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Perrigo

In other Perrigo news, EVP Ronald Craig Janish sold 13,000 shares of the firm's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $29.40, for a total value of $382,200.00. Following the transaction, the executive vice president now directly owns 20,553 shares of the company's stock, valued at $604,258.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Perrigo news, Director Katherine C. Doyle sold 8,954 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $27.30, for a total transaction of $244,444.20. Following the transaction, the director now directly owns 6,009 shares in the company, valued at $164,045.70. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ronald Craig Janish sold 13,000 shares of the company's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $29.40, for a total transaction of $382,200.00. Following the completion of the sale, the executive vice president now owns 20,553 shares in the company, valued at approximately $604,258.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,254 shares of company stock worth $1,411,969 in the last three months. 0.70% of the stock is currently owned by company insiders.

Perrigo Price Performance

Shares of Perrigo stock traded up $0.01 on Friday, hitting $25.09. The company's stock had a trading volume of 804,794 shares, compared to its average volume of 1,609,844. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $3.42 billion, a P/E ratio of -358.43 and a beta of 0.48. The firm has a fifty day moving average price of $26.66 and a 200-day moving average price of $27.76. Perrigo Company plc has a 52-week low of $23.89 and a 52-week high of $34.60.

Perrigo (NYSE:PRGO - Get Free Report) last announced its earnings results on Friday, August 2nd. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.07. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.13 billion. Perrigo had a negative net margin of 2.81% and a positive return on equity of 6.79%. Perrigo's revenue was down 10.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.63 earnings per share. On average, equities research analysts expect that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 17th. Stockholders of record on Friday, August 30th were issued a $0.276 dividend. The ex-dividend date of this dividend was Friday, August 30th. This represents a $1.10 dividend on an annualized basis and a dividend yield of 4.40%. Perrigo's dividend payout ratio (DPR) is -1,571.43%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. StockNews.com cut Perrigo from a "buy" rating to a "hold" rating in a research note on Friday. Canaccord Genuity Group reiterated a "buy" rating and set a $42.00 price target on shares of Perrigo in a research note on Monday, September 30th. Piper Sandler lowered their target price on shares of Perrigo from $36.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, July 11th. Finally, Jefferies Financial Group reissued a "hold" rating and set a $30.00 price objective (down from $50.00) on shares of Perrigo in a research report on Monday, September 23rd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $37.00.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.